Marker Therapeutics slides after $16 mln private placement

Marker Therapeutics

19/12/2024 13:29

** Shares of drug developer Marker Therapeutics  MRKR.O 
fall 25.5% to $3 premarket
    ** MRKR announces $16.1 mln private placement
    ** Proceeds from this financing will support the clinical
development of MT-601, a next-generation T cell-based therapy
for relapsed lymphoma patients - MRKR
    ** Investors to pay a purchase price of $3.20/shr and
warrants are exercisable for $4.03/shr
    ** As of last close, stock has fallen 26.7% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))